Genomica Corporation Announces Availability of Discovery Manager 3.0.

Business Editors, Health & Medical Writers

BIOWIRE2K

BOULDER, Colo.--(BW HealthWire)--March 22, 2001

Genomica Corporation (Nasdaq:GNOM):

SNP-Enabled Upgrade Extends Reach of Enterprise Product and Previews

Functionality for New Oracle/Java-Based Product Line

Genomica Corporation (Nasdaq:GNOM), a leading developer of software products that facilitate drug discovery and development, today announced the availability of Discovery Manager(TM) 3.0, the latest version of its highly regarded genetic analysis product suite.

This upgrade significantly extends Discovery Manager's genotyping, sequencing, and visualization capabilities. Among the enhancements is the new capability to integrate SNP data from Orchid BioSciences' SNPstream(R) 25K genotyping platform into Discovery Manager's powerful analytical toolset, which already includes links to such widely used tools as Simwalk2(TM), Genehunter(TM), and PedCheck(TM), as well as Genomica's own Frequency and Haplotype Managers. This latest release hints at the functional range of Genomica's new product line, expected later this year, which will be based on industry-standard Java(TM) and Oracle(R) technologies.

"We are delighted to announce this new release of Discovery Manager," said Genomica CEO Teresa Ayers. "The updated functionality for Discovery Manager reflects our ongoing commitment to our customers. Research groups invest a great deal in genetic data management and analysis, and whether we are talking about Discovery Manager or our upcoming Oracle-based products, we want our customers to understand that we will continue to support their needs over time. We are especially pleased to be able to offer our analysis tools to users of Orchid's advanced genotyping technology."

"Genomica's decision to include an interface for SNPstream users in the new release of Discovery Manager is a further demonstration of the increasingly widespread acceptance of Orchid's SNP-IT(TM) as a leading genotyping technology," said Michael Pettigrew, Executive Director of Sales and Marketing of Orchid's Life Sciences Group. "As the customer base for our SNPstream 25K platform continues to grow, we are pleased that they will have the option of using Genomica's powerful downstream analysis tools to create databases and customized analyses."

Discovery Manager 3.0 offers enhanced functionality across the full range of its enterprise-wide features, benefiting scientists by allowing them to centralize project data, create searchable databases, and customize their analyses. "I've been very impressed with the high quality of service from Genomica," said Paul August, Senior Associate Scientist and Manager of Full-length Cloning at Aventis Pharma Drug Innovation & Approval (NYSE:AVE). "Our current use of the Discovery Manager product has improved our efficiency. By delivering these product enhancements in such a timely manner, Genomica will help us further increase our operational efficiency."

About Genomica Corporation

Genomica Corporation develops and markets innovative software products and services that enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. Genomica's customers include leading genomics-based research organizations such as AstraZeneca, GlaxoSmithKline, Aventis, Pfizer, and the National Cancer Institute. Genomica is also collaborating with Applied Biosystems to develop software products to be used with AB's industry-leading hardware for drug discovery. For additional information on Genomica, please visit its Website at www.genomica.com.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Genomica Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Genomica Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such factors include, but are not limited to, quarterly fluctuations in Genomica's revenues or other operating results, failure by Genomica to meet financial expectations of analysts and investors, reliance by Genomica on a limited number of customers for a majority of its revenue, Genomica's reliance on key personnel, risks as related to market acceptance of Genomica's product, rapid technological change in Genomica's market, potential defects associated with Genomica's product, Genomica's need to maintain and enhance strategic relationships with larger companies, Genomica's ability to expand its sales and marketing departments, Genomica's ability to manage growth, Genomica's use in its product of third-party components, activities by Genomica and others regarding protection of intellectual property, release of competitive products and other actions by competitors, and economic downturns in either domestic or foreign markets. Further details on these risks and other risks are set forth in Genomica's filings with the Securities and Exchange Commission. These filings are available on a website maintained by the Securities and Exchange Commission on the world wide web at www.sec.gov. Genomica does not undertake an obligation to update forward-looking statements.

Discovery Manager is a trademark of Genomica Corporation. SNPstream, PedCheck, Simwalk2, Genehunter, Java, and Oracle are trademarks of their respective owners.